Member Info for BuenaVista

"She has nearly four years worth of positive in - clinic data in her handbag, yet she is incapable of selling it , she doesn’t possess the skillset."

Moving swiftly over the misogyny, although I don't discount that as the root of your antagonism towards her, what skillset do you think she doesn't possess? ...Bearing in mind that the people she, and Simon Bennett, are 'selling' to are extremely knowledgeable and sophisticated people, responsible for very large budgets, not the crowd buying spuds down at the local market.

The link between Avacta and Abenza is Laura Weatherburn, who contributed to the AffDC poster presented at EORTC-NCI-AACR in Barcelona in October 2024: https://abzena.com/resource/affimer-drug-conjugates-affdc-targeting-fibroblast-activation-protein/

From her LinkedIn profile, she has been working as Scientist II (promoted to Senior Scientist last week), Bioconjugation at Abenza in Cambridge, UK since April 2022: https://www.linkedin.com/in/laura-weatherburn-85662a130/

She described her work (as it was up until last week, at lreast) as primarily "producing bioconjugates for client projects, covering a wide scope of linker technologies and protein formats" and posted about the AffDC collaboration four months ago: https://www.linkedin.com/feed/update/urn:li:activity:7262717183401553920/

She also describes her experience as:

- Bioconjugation to antibodies, bispecific antibodies, antibody fragments and recombinant proteins.

- Experience covering classical bioconjugation chemistry (e.g maleimide, NHS-ester, DBCO), enzymatic reactions (BTGase), and disulfide rebridging reagents (ThioBridge®)

- Conjugation of a wide range of cytotoxic reagents (e.g MMAE, Dxd), oligonucleotides and fluorescent dyes.

- Functionalisation and purification of oligonucleotides for conjugation

- Experience in working with small scale production of ADC's (1 mg) to multigram (5 g) amounts

- Purification of conjugates produced (SEC, HIC, IEX, Affinity, TFF)

- Analysis of ADC's and linker-payloads (Analytical-HIC, SEC, LC-MS, IEX, UV-Vis, SDS-PAGE and RP-HPLC)

The Abenza site is very close to the old Avacta site outside Cambridge so I would hazard a guess that Abenza's activities and possibly Laura Weatherburn herself were known to Avacta and so were an obvious contractor if the necessary bioconjugation skills and experience didn't reside inhouse.

AgentB, so you're saying Avacta follows European stock movements? Is this a new theory?

It's another Orange Jesus miracle!

VR is absolutely correct. All breast cancer patients are now on the pill. AZ packing up business and moving to China, Merck gone bankrupt, Novartis building a Mars ship. What have we done? What could we have been thinking of!?!

Explained: https://youtu.be/WeugL6jV3W4?si=iY9el4Q5ymiRckd7&t=176

"...and an injury to Trump's ear."

Remember how, when his ear lobe (sic) was hit, the Orange Jesus touched the wound and it was miraculously healed?

"70 + countries are lined up to cut a deal.." is yet another Trump lie.

Just market manipulation for his mates with the insider information. He did it in his first term but this time it's even more blatant.

Nah, it's simpler than that. Capitalism is just a giant Ponzi scheme, borrowing money from the future to funnel it to the already rich, and democracy has put it on steroids as the political parties have to bribe the populace to vote for them.

Last I heard, pharmaceuticals were exempted from tariffs, probably an indication of the power big pharma holds over the economy and Trump's meds. But the guy is so unstable and unpredictable, that could all change if one of his meds stops working.

It's absolutely clear what he's doing. He intends to make the US into an impoverished country that doesn't import much, thus completely reversing the balance of trade balance so that the US can itself be horrid and treat other countries very unfairly.

"why does the UK charge both?"

Which 'both' are you referring to?

It's absolutely standard within the pharma industry to employ KOLs (key opinion leaders) to get a company's message out. Such people, 'influencers' who are respected by their peers for their knowledge and expertise, network with industry practitioners directly and indirectly but clearly not with Professor Eggy.

The only thing Professor Eggy knows is the meaning of demeaning.

...even if a dump could put out a fire...

in case of any doubt, i wouldn't **** on wyndrum if it was on fire.

I disagree. Flipper is totally ambivalent about Avacta's success or otherwise, about a revolutionary new treatment for cancer or not. Flipper is only interested in money. Lots of lovely loverly gorgeous mega mega MEGA amounts of money, Money, MONEY! Unfortunately (for Flipper), Mr Harland & Wolff Helium One to de base himself is, HeHe, one lousy, lousy gambler. So sad. So, so, so very sad. Never mind.😁

Well if £40m for licensing out the STS indication then that would also come with milestone payments and royalties ...btw, what's happened with milestone payments for Avacta's current licence agreements? We've not had any for ages.

My point was why invest precious resources in a prodrug of a new proteasome inhibitor, completely untested in humans and not even at IND stage, when it has only ~10 years of patent life remaining if you can produce a prodrug of well-tested and characterised bortezomib with 20+ years before patent expiry.

As it turned out for AVA3996, its value has solely been in showing that pre|CISION worked with a second prodrug, albeit only as far as in invitro human cells and invivo animal models, but analogous to how well AVA6000 worked. AVA6103 confirms again that pre|CISION works in early development models.

I think a lot will depend on the broader market this year and whether the major stocks continue to fall at the start of the week or stage a recovery.